Showing 7511-7520 of 8879 results for "".
- FDA Approves Merck’s Keytruda for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Not Curable by Surgery or Radiationhttps://practicaldermatology.com/news/fda-approves-mercks-keytruda-for-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-not-curable-by-surgery-or-radiation/2460445/The FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in both three and six week dosing options as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
- Cynosure Reopening Survey: If You Wear Masks, They Will Come Backhttps://practicaldermatology.com/news/cynosure-reopening-survey-if-you-wear-masks-they-will-come-back/2460441/Fully 85 percent of people plan to return to aesthetic treatments within 12 months of COVID-19 restrictions being lifted, and 63 percent plan to return to practices within just three months of restrictions being lifted in their respective countries, according to a
- Regenerative Medicine Business News: Bimini Acquires Healeonhttps://practicaldermatology.com/news/regenerative-medicine-business-news-bimini-acquires-healeon/2460432/Bimini Health Tech has acquired Healeon Medical, Inc., a company that designs, develops, manufactures, and markets medical devices for autologous, point-of-care treatments. Healeon's products include: the signature HD PRP system which fe
- Burt's Bees Natural Retinol Alternative Works Well in Sensitive Skinhttps://practicaldermatology.com/news/burts-bees-natural-retinol-alternative-works-well-in-sensitive-skin/2460430/Three new studies from Burt’s Bees highlight the safety and efficacy of Bakuchiol, a natural retinol alternative, as well as a new facial oil and lip balm. The findings were presented online at the American Academy of Dermatology (AAD
- Johnson & Johnson Consumer Health Research Sheds Light on the Development of the Skin Microbiomehttps://practicaldermatology.com/news/johnson-johnson-consumer-health-research-sheds-light-on-the-development-of-the-skin-microbiome/2460428/New Johnson & Johnson Consumer Health research provides key insights into how the infant microbiome develops from birth to childhood. The findings, based on 10 years of data, were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.
- Juvéderm Voluma XC Approved for Enhancement of the Chin Regionhttps://practicaldermatology.com/news/juvederm-voluma-xc-approved-for-enhancement-of-the-chin-region/2460426/The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest ap
- Late-Breaking Data: Lilly and Dermira’s Lebrikizumab Improves Itch, Sleep and Quality of Life in ADhttps://practicaldermatology.com/news/late-breaking-data-lilly-and-dermiras-lebrikizumab-improves-itch-sleep-and-quality-of-life-in-ad-1/2460424/Lilly and Dermira’s Lebrikizumab improves itch, sleep and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to a Phase 2b clinical trial presented during a virtual late-breaking, oral session at the American Academy of Dermatology (AAD) 2020 Annual Meetin
- New from Obagi: Two Sunscreens and a Hydrating Serumhttps://practicaldermatology.com/news/new-from-obagi-two-sunscreens-and-a-hydrating-serum/2460415/Obagi is launching two new Physical Defense Sunscreens and Daily Hydro-Drops. The new SUZANOBAGIMD Physical Defense Sunscreens, available in broad-spectrum SPF 40 and tinted SPF 50, defend against five light sources, including high energy visible light, or blue light, visible light
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Zilxi Approved: First Topical Minocycline Treatment for Rosaceahttps://practicaldermatology.com/news/zilxi-approved-first-topical-minocycline-treatment-for-rosacea/2460408/The FDA has approved Zilxi™ (minocycline) topical foam, 1.5%, from Menlo Therapeutics for the treatment of inflammatory lesions of rosacea in adults. Zilxi, developed as FMX103 by Menlo’s wholly-owned subsidiary Foamix Pharmaceuticals Ltd., is the first minocycline product of any kind